ReviewGynecologic oncology reports2025
Trastuzumab monotherapy as maintenance treatment for metastatic HER2+ vulvar Paget disease: systematic review and case report.
Review in Gynecologic oncology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Treatment Strategies for Extramammary Paget Disease: A Narrative Review of Current Status and Future Directions.Cancers · 2026Review
- Metastatic extramammary Paget's disease successfully treated by trastuzumab deruxtecan: a rare case report.Frontiers in medicine · 2026Article
- Trastuzumab deruxtecan treatment for HER2-low metastatic scrotal extramammary Paget's disease with bone marrow involvement: a case report.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vulvar Paget's disease (VPD) is a rare intraepithelial malignancy frequently associated with HER2 overexpression. This study offers insights into managing HER2-positive extramammary Paget's disease cases in which trastuzumab monotherapy was administered as manteinance therapy. We report the case of a 52-year-old woman with VDP and lymph node involvement, who was initially treated with paclitaxel and trastuzumab, for which chemotherapy was discontinued due to significant side effects, and trastuzumab as maintenance therapy was continued, resulting in significant regression of metastatic lesions. Additionally, a systematic review was conducted. The review included 6 studies from 2008 to 2020. Complete response was achieved in 2 out of 7 (28.6%) cases, partial response in 4 (42.9%) cases, and stable disease in 1 (14.3%) case. Mild moderate headache and flushing during trastuzumab manteinance therapy were reported in only one patient. In conclusion, trastuzumab monotherapy may be a valid alternative option, particularly in patients unable to tolerate combination chemotherapy. These findings emphasize the importance of personalized treatment approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.